27 February 2014 - As of February 15, Newfoundland joins seven other provinces in providing individuals living with schizophrenia access to Invega Sustenna (paliperidone palmitate), a long-acting monthly treatment option. Available through the Newfoundland and Labrador Prescription Drug Program, Invega Sustenna is indicated for the treatment of schizophrenia in adults (18 years and older).

Newfoundland is the eighth province in Canada to include Invega Sustenna on their public formularies, joining British Columbia, Alberta, Saskatchewan, Ontario, Quebec, Nova Scotia and New Brunswick.

For more details, go to: http://ca.finance.yahoo.com/news/invega-sustenna-now-reimbursed-newfoundland-110000722.html